| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -27.95 M USD | -38.77 M USD | -41.81 M USD | -72.34 M USD | -47.18 M USD | -21.52 M USD |
| Depreciation & Amortization | 1.09 M USD | 1.01 M USD | 1.05 M USD | 1.01 M USD | 726000 USD | 289000 USD |
| Stock-Based Compensation | 2.80 M USD | 4.36 M USD | 4.74 M USD | 10.65 M USD | 6.90 M USD | 1.12 M USD |
| Capital Expenditures | 1.19 M USD | 383000 USD | 804000 USD | 585000 USD | 2.71 M USD | 1.57 M USD |
| Cash Flow from Investing | -1.19 M USD | -383000 USD | -804000 USD | -585000 USD | -2.71 M USD | -1.57 M USD |
| Cash Flow from Financing | 27.50 M USD | 1.02 M USD | 174000 USD | 7000 USD | 176.77 M USD | 60.94 M USD |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | -29.13 M USD | -39.15 M USD | -42.61 M USD | -72.92 M USD | -49.89 M USD | -23.09 M USD |
Hyperfine Inc., a pioneering medical technology firm, develops portable, low-cost magnetic resonance imaging (MRI) systems known for their accessibility and transformative potential in healthcare. Hyperfine's flagship product, the Swoop Portable MRI, is designed to significantly enhance patient care by enabling real-time, bedside imaging, thus extending MRI capabilities beyond traditional clinical settings. This innovation is particularly impactful in emergency rooms, intensive care units, and remote locations where access to conventional MRI facilities may be limited or non-existent. By bridging the gap between advanced imaging and practical application, Hyperfine Inc. plays a crucial role in democratizing healthcare access, speeding up diagnosis, and ultimately improving clinical outcomes. The company’s focus on innovation and accessibility positions it as a key player in the med-tech industry, potentially influencing hospital operations, patient management protocols, and healthcare delivery frameworks worldwide.